AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11599648
Drug: Once-daily fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily fluoxetine (20 mg/day)
Trial: 9040303
Drug: Famciclovir 125
RxNorm normalized name: famciclovir 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 125 mg twice daily
Trial: 8187255
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil 30 micrograms (0.6 ml) in 4.4 ml lidocaine carbonate 2% with 5 micrograms.ml‐1 epinephrine
Trial: 8187255
Drug: Lidocaine carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine carbonate 2% with 5 micrograms.ml‐1 epinephrine (Control Group)
Trial: 31530227
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) therapy (10 Hz, 600 pulses, 70% resting motor threshold amplitude)
Trial: 31530227
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) therapy
Trial: 31411696
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery
Trial: 31411696
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF)
Trial: 27649982
Drug: ONO-9054 (0.003%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-9054 (0.003%, 30 μg/mL) once daily for 28 days
Trial: 27649982
Drug: Xalatan (0.005%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xalatan (0.005%, 50 μg/mL) once daily for 28 days
Trial: 24075603
Drug: Asenapine (ASE:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine (ASE: 5-10mg twice-daily)
Trial: 24075603
Drug: Olanzapine (OLA:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (OLA: 5-20mg once-daily)
Trial: 19208649
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of unselected mononuclear cells (UNSEL)
Trial: 19208649
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of selected CD34(+)CXCR4(+) cells (SEL)
Trial: 19208649
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CTRL) without BM cell treatment
Trial: 10853626
Drug: Aspirin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (low dosages < or = 100 mg/day)
Trial: 10853626
Drug: Aspirin (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (higher dosages)
Trial: 3572208
Drug: Labetalol 100
RxNorm normalized name: HCTZ 25/LABETALOL 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 100 mg
Trial: 17105584
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g alcohol (group 1)
Trial: 15336468
Drug: Tramadol/Acetaminophen 75/650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/Acetaminophen 75/650 mg (Tr/Ac)
Trial: 15336468
Drug: Codeine/Acetaminophen/Ibuprofen 20/500/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine/Acetaminophen/Ibuprofen 20/500/400 mg (Co/Ac/Ib)
Trial: 2502165
Drug: Nalbuphine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (15 mg 70 kg-1)
Trial: 2502165
Drug: Nalbuphine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (30 mg 70 kg-1)
Trial: 2502165
Drug: Nalbuphine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (60 mg 70 kg-1)
Trial: 2502165
Drug: Nalbuphine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (all doses)
Trial: 2502165
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 mg 70 kg-1)
Trial: 12953943
Drug: CPC+ TO
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPC+ TO (clocortolone pivalate cream 0.1% + tacrolimus ointment 0.1%)
Trial: 11139095
Drug: Antiarrythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrythmic drugs
Trial: 11139095
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment modalities
Trial: 9087151
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray 200 micrograms bid
Trial: 9087151
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aqueous nasal spray 200 micrograms bid
Trial: 8436162
Drug: Antacid (aluminium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (aluminium hydroxide 800 mg and magnesium hydroxide 800 mg), tid, added to a stable regimen of theophylline SR bid for 4 days.
Trial: 3963039
Drug: 2 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml/kg of 100-proof vodka in orange juice
Trial: 27186550
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU of Vitamin D daily (Group 1)
Trial: 27186550
Drug: 30,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30,000 IU of Vitamin D monthly (Group 2)
Trial: 27186550
Drug: 2000 IU
RxNorm normalized name: D 2000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU of Vitamin D daily (Group 3)
Trial: 27186550
Drug: 60,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60,000 IU of Vitamin D monthly (Group 4)
Trial: 27186550
Drug: Group 2K
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2K (2000 IU daily and 60,000 IU monthly)
Trial: 27186550
Drug: Group 1K
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1K (1000 IU daily and 30,000 IU monthly)
Trial: 16634338
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy programme
Trial: 10946866
Drug: Ad libitum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad libitum intake after each treatment period
Trial: 8610913
Drug: Edrophonium 1
RxNorm normalized name: edrophonium 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1 mg/kg with atropine 10 micrograms/kg given when NMT of the AP was 1% or 10% of baseline
Trial: 3571043
Drug: Gentamicin bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin bolus iv injection (80 mg)
Trial: 3571043
Drug: Gentamicin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin infusion over 15 min (80 mg)
Trial: 16901186
Drug: Sertaconazole nail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertaconazole nail patch (3.63 mg)
Trial: 16901186
Drug: Control patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patch (no antifungal agent)
Trial: 12799627
Drug: 5-FU/FA (5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/FA (5-FU 425 mg m(‐2) i.v. and FA 20 mg m(‐2) i.v. bolus days 1‐5 every 28 days for 6 months
Trial: 12799627
Drug: PVI 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PVI 5-FU (300 mg m(‐2) day for 12 weeks)
Trial: 9928753
Drug: felodipine-metoprolol 5/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felodipine-metoprolol 5/50 mg once daily
Trial: 7495045
Drug: benazepril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril (10-20 mg once a day)
Trial: 2312804
Drug: Modified iontophoretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified iontophoretic method with an anticholinergic agent and aluminum chloride
Trial: 648378
Drug: Prednisone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (15 mg/day)
Trial: 648378
Drug: Azathioprine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2 mg/kg daily)
Trial: 648378
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prednisone (10 mg/day) and azathioprine (2 mg/kg daily)
Trial: 24742343
Drug: PursuingPleasure (PP)
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PursuingPleasure (PP) - online cognitive behavioral therapy program with mindfulness training and chat groups
Trial: 19591723
Drug: Placebo (hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (hand cream)
Trial: 16490874
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium (10 mg)
Trial: 16490874
Drug: Pseudoephedrine hydrochloride
RxNorm normalized name: Pseudoephedrine Hydrochloride
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine hydrochloride (240 mg)
Trial: 15575054
Drug: Flecainide or
RxNorm normalized name: flecainide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide or propafenone (self-administered)
Trial: 9264305
Drug: Betatolol 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betatolol 0.25% suspension
Trial: 3718378
Drug: Spironolactone, 25
RxNorm normalized name: Spironolactone, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone, 25 mg PO QID for 48 h prior to and during exposure
Trial: 30400570
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (1 × 10^10 CFU per day)
Trial: 30400570
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (2.5 × 10^8 CFU per day)
Trial: 20858857
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid-based therapy (in 155 patients with M3V)
Trial: 20858857
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid-based therapy (in 748 patients with classical M3)
Trial: 16389183
Drug: Sequential BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential BCG and electromotive mitomycin
Trial: 10355866
Drug: Fluvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin treatment for 12 weeks
Trial: 10355866
Drug: Fluvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin treatment after placebo for long-term
Trial: 6183898
Drug: Oral D-penicillamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D-penicillamine
Trial: 29782224
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg every 2 weeks for 24 weeks)
Trial: 24581894
Drug: Shortened form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened form of problem-solving therapy focusing on caregiver burden
Trial: 22149151
Drug: Controlled-release aceclofenac
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release aceclofenac 200 mg od (Clanza CR®)
Trial: 22149151
Drug: Immediate-release aceclofenac
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release aceclofenac 100 mg bid (Airtal®)
Trial: 22149151
Drug: Controlled-release aceclofenac
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release aceclofenac 200 mg od (Clanza CR®) fed state
Trial: 22149151
Drug: Controlled-release aceclofenac
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release aceclofenac 200 mg od (Clanza CR®) fasted state
Trial: 16039293
Drug: 17beta-estradiol 1mg
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol 1mg daily
Trial: 11966505
Drug: Mosapride 5
RxNorm normalized name: mosapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride 5 mg b.d.
Trial: 11966505
Drug: Mosapride 10
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride 10 mg b.d.
Trial: 11966505
Drug: Mosapride 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride 7.5 mg t.d.s.
Trial: 8065590
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (3.75 mg/monthly)
Trial: 8065590
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg/daily)
Trial: 2967780
Drug: Tizanidine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (4 mg three times daily)
Trial: 31628887
Drug: Patient counselling
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient counselling covering asthma knowledge, control, adherence to treatment and inhalation techniques
Trial: 25300460
Drug: Nilvadipine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (8 mg overencapsulated, sustained release capsule)
Trial: 25300460
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching overencapsulated sugar pill)
Trial: 22791756
Drug: T gel
RxNorm normalized name: Joint Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T gel 10 g + NES gel 8 mg
Trial: 22791756
Drug: T gel
RxNorm normalized name: Joint Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T gel 10 g + NES gel 12 mg
Trial: 22791756
Drug: T gel
RxNorm normalized name: Joint Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T gel 10 g + NES 0 mg (placebo)
Trial: 2519530
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg per day, tapered to 20 mg per day)
Trial: 2519530
Drug: Cyclosporine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (7.5 mg per kilogram of body weight per day)
Trial: 2519530
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclosporine and low dose prednisone
Trial: 31727538
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily until PSA progression followed by enzalutamide 160 mg orally once daily (group A)
Trial: 31727538
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg orally once daily (as second-line therapy after abiraterone)
Trial: 31727538
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily (as second-line therapy after enzalutamide)
Trial: 26254706
Drug: Beta2-microglobulin >1.92
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta2-microglobulin >1.92 mg/L
Trial: 26254706
Drug: C-peptide <1.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-peptide <1.32 ng/ml
Trial: 26254706
Drug: C-peptide <2.22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-peptide <2.22 ng/ml
Trial: 19033149
Drug: Internet-based problem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based problem solving therapy (PST)
Trial: 6363079
Drug: Lidoflazine and
RxNorm normalized name: Lidoflazine
DrugBank: Lidoflazine (DB13766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidoflazine and propranolol combination
Trial: 22727431
Drug: Non-ASV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ASV treatment
Trial: 18076864
Drug: TiF(4) solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TiF(4) solution applied (ERO+F)
Trial: 18076864
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (ERO+no-F)
Trial: 11841884
Drug: Verapamil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil infusion at a rate of 1 mg/min to a maximum of 20 mg
Trial: 11841884
Drug: Diltiazem infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem infusion at a rate of 2.5 mg/min to a maximum of 50 mg
Trial: 7772352
Drug: Macintosh laryngoscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macintosh laryngoscope (Group L)
Trial: 2286469
Drug: Nitrofurantoin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin (200 mg per day for one week)
Trial: 323118
Drug: Atropine 2-4
RxNorm normalized name: atropine 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 2-4 mg/day
Trial: 323118
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g/day and Atropine 2-4 mg/day
Trial: 31163975
Drug: Syndemic factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syndemic factors (e.g., polydrug use, hazardous alcohol consumption, client‐perpetrated violence, depression, and sexually transmitted infections)
Trial: 31300264
Drug: Caloric vestibular
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric vestibular stimulation (CVS) via a portable device, self-administered twice daily for 8 weeks.
Trial: 31300264
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (no specific details provided).
Trial: 28961838
Drug: R-CHOP administered
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP administered every 14 days with CNS prophylaxis (IT methotrexate)
Trial: 28961838
Drug: R-CHOP administered
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP administered every 21 days with CNS prophylaxis (IT methotrexate)
Trial: 24932945
Drug: Self-reported drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported drug use
Trial: 18778385
Drug: Drug Information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Information and Advice (Control)
Trial: 16914772
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group (standard treatment alone)
Trial: 12809330
Drug: Heptavalent conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heptavalent conjugate vaccine
Trial: 10894286
Drug: famciclovir 500
RxNorm normalized name: famciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famciclovir 500 mg twice a day
Trial: 10894286
Drug: acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acyclovir 400 mg five times a day
Trial: 6505269
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of alpha 2 Interferon (20 X 10(6) I.U./m2 subcutaneously three times weekly for 3 months)
Trial: 6505269
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of alpha 2 Interferon (50 X 10(6) I.U./m2 intravenously daily for 5 consecutive days every 4 weeks)
Trial: 29945650
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) with telephone support
Trial: 26756623
Drug: Object-related bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Object-related bilateral symmetrical training with mirror therapy (MT)
Trial: 25306688
Drug: Epidural blockade
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blockade with local anesthetics and small doses of steroids
Trial: 12399273
Drug: 1 mmol
RxNorm normalized name: monobasic potassium phosphate 1 MMOL/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mmol arginine/kg lean body mass + 25 g glucose
Trial: 12399273
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g glucose alone
Trial: 24444781
Drug: Medium-dose ASA
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose ASA
Trial: 22531418
Drug: γ-secretase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: γ-secretase inhibitor semagacestat (100 mg)
Trial: 22531418
Drug: γ-secretase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: γ-secretase inhibitor semagacestat (140 mg)
Trial: 22531418
Drug: γ-secretase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: γ-secretase inhibitor semagacestat (280 mg)
Trial: 20805115
Drug: E5555 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5555 (50 mg)
Trial: 20805115
Drug: E5555 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5555 (100 mg)